Published January, 2010
By Dan Jones
Publisher: Springer (Humana Press Inc.)
Series: Contemporary Hematology
Rating: 5.00
Availability: Available

This text on hematopathology integrates clinical and experimental studies with diagnostic criteria. It connects the field with recent advances in immunology research and includes coverage of myeloid, lymphoid tumors and transplant biology.

---

Published January, 2010
By Rene-Olivier Mirimanoff, Mahmut Ozsahin, Yazid Belkacemi and Romain Bosc
Publisher: Springer (Springer Editions)
Rating:
Availability: Available

Why a book dedicated to rare cancer management? Given the large variety of rare cancers,they take up a significant part of our daily practice. Therefore, we owe it to our patients with rare tumours that we use the knowledge gained in the treatment of the more common cancers to provide them with a better future.

---

Published January, 2010
By Howard A. Liebman and Howard Liebman
Publisher: Elsevier (W B Saunders Co Ltd)
Series: The Clinics: Internal Medicine
Rating:
Availability: Available

Chronic immune thrombocytopenia is a disease in which the immune system destroys platelets (blood cells involved in the clotting process). This title includes articles that focus on the traditional and newer treatments for the disease.

---

Published December, 2009
By Motonari Kondo
Publisher: Springer (Humana Press Inc.)
Series: Stem Cell Biology and Regenerative Medicine
Rating:
Availability: Available

In the summer of 1988, my developmental biology professor announced to the class that hematopoietic stem cells (HSCs) had finally been purified.

---

Published December, 2009
By Michael Kleinberg
Publisher: Springer (Humana Press Inc.)
Series: Contemporary Hematology
Rating: 1.00
Availability: Available

In Managing Infections in Patients with Hematological Malignancies, the authors and editor draw on their extensive expertise while providing a roadmap for hematologists to efficiently manage the complex infections within their patients.

---

Published December, 2009
By Maurie Markman and Razelle Kurzrock
Publisher: Springer (Humana Press Inc.)
Series: Current Clinical Oncology
Rating: 0.00
Availability: Available

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics.

---

Published November, 2009
By Alessandro Comaru Pasqualotto
Publisher: Springer
Rating:
Availability: Available

Aspergillosis is an infection that mostly affects the respiratory system but can involve any other system in the body. This book examines the current state of the art in the prevention, diagnosis, therapy and management of all forms of aspergillosis.

---

Published November, 2009
By Uwe M. Martens
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Series: Recent Results in Cancer Research
Rating:
Availability: Contact supplier

Written by acknowledged experts, this text provides a broad overview of the small molecules currently used for the treatment of malignant diseases, and discusses interesting novel compounds that are in the process of clinical development to combat cancer.

---

Published November, 2009
By Meinrad Gawaz, Bernd Pötzsch, Katharina Madlener, Christine Mannhalter, Margarethe Geiger, Harald Langer and Bernd Poetzsch
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Rating:
Availability: Available

Das neue Standardwerk fur Weiterbildung und klinische Praxis: Von den molekularen Grundlagen bis zur praktisch-klinischen Fragestellung, von den klassischen Gebieten bis zu aktuellen Aspekten der Endothelzellbiologie umfasst das Lehr- und Nachschlagewerk das gesamte Wissensspektrum der Hamostaseologie.

---

Published November, 2009
By Lalitha Nagarajan
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Treatment and Research
Rating:
Availability: Available

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

---